Correction of Pathological Accumulation of Glycosaminoglycans in Central Nervous System and Peripheral Tissues of MPSIIIA Mice Through Systemic AAV9 Gene Transfer
Albert Ruzo(Dana-Farber Cancer Institute), Fátima Bosch(Universitat Autònoma de Barcelona), Miquel García(Universitat Autònoma de Barcelona), Eduard Ayuso(Gene Therapy Laboratory), Albert Ribera(Gene Therapy Laboratory), Pilar Villacampa(Josep Carreras Leukaemia Research Institute), Sara Marcó(Universitat Autònoma de Barcelona), Virginia Haurigot(Spark Therapeutics (United States)), Federico Mingozzi(Spark Therapeutics (United States)), Lucca Maggioni(Universitat Autònoma de Barcelona)
Cited by 105
Related Papers
Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
|Science Translational Medicine|2013|346
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy
|Journal of Clinical Investigation|2013|232
Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells
|Blood|2013|160
Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase
|Science Translational Medicine|2017|133